[1] [1] COOK G J R, THORPE M P. Bone metastases[J]. Cancer J, 2024,30(3): 202-209. DOI:10.1097/PPO.0000000000000717.

[2] [2] KIM Y J, KIM S H, KIM J W,et al. Gastric cancer with initial bone metastasis: a distinct group of diseases with poor prognosis[J]. Eur J Cancer, 2014, 50(16): 2810-2821. DOI:10.1016/j.ejca.2014.08.003.

[3] [3] TAKEI D, TAGAMI K. Management of cancer pain due to bone metastasis[J]. J Bone Miner Metab, 2023, 41(3): 327-336. DOI:10.1007/s00774-022-01382-y.

[5] [5] LANDI L, D'INC F, GELIBTER A,et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer[J/OL]. J Immunother Cancer, 2019, 7(1): 316[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/31752994/. DOI:10.1186/s40425-019-0793-8.

[6] [6] LI X, WANG L, CHEN S H,et al. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors[J]. Thorac Cancer,2020, 11(10): 2812-2819. DOI:10.1111/1759-7714.13597.

[7] [7] VENETIS K, PICIOTTI R, SAJJADI E,et al. Breast cancer with bone metastasis: molecular insights and clinical management[J/OL]. Cells,2021, 10(6): 1377[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/34199522/. DOI:10.3390/cells10061377.

[8] [8] ALI A, HOYLE A, HARAN M,et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2021, 7(4): 555-563. DOI:10.1001/jamaoncol.2020.7857.

[9] [9] SCAGLIOTTI G V, HIRSH V, SIENA S,et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumabversuszoledronic acid: subgroup analysis from a randomized phase 3 study[J]. J Thorac Oncol, 2012, 7(12):1823-1829. DOI:10.1097/JTO.0b013e31826aec2b.

[10] [10] TURKOZ F P, SOLAK M, KILICKAP S,et al. Bone metastasis from gastric cancer: the incidence, clinicopathological features, and influence on survival[J]. J Gastric Cancer, 2014, 14(3): 164-172. DOI:10.5230/jgc.2014.14.3.164.

[11] [11] SUN P C, ANTWI S O, SARTORIUS K,et al. Tumor microenvironment, clinical features, and advances in therapy for bone metastasis in gastric cancer[J/OL]. Cancers, 2022, 14(19): 4888[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/36230816/. DOI:10.3390/cancers14194888.

[12] [12] ZHAO Q W, QUAN Z, LIU S S,et al. Heterogeneity and prognosis of single organ metastases in gastric cancer[J/OL]. Transl Gastroenterol Hepatol, 2024, 9: 61[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/39503034/. DOI:10.21037/tgh-24-11.

[13] [13] IMURA Y, TATEIWA D, SUGIMOTO N,et al. Prognostic factors and skeletal-related events in patients with bone metastasis from gastric cancer[J/OL]. Mol Clin Oncol, 2020, 13(4): 31[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/32765878/. DOI:10.3892/mco.2020.2101.

[14] [14] JANJIGIAN Y Y, SHITARA K, MOEHLER M,et al. First-line nivolumab plus chemotherapyversuschemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649）: a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI:10.1016/S0140-6736(21)00797-2.

[15] [15] REN G W, ESPOSITO M, KANG Y B. Bone metastasis and the metastatic niche[J]. J Mol Med, 2015, 93(11): 1203-1212. DOI:10.1007/s00109-015-1329-4.

[16] [16] ZRAIK I M, HE-BUSCH Y. Management von nebenwirkungen der chemotherapie und deren langzeitfolgen[J]. Der Urol, 2021, 60(7): 862-871. DOI:10.1007/s00120-021-01569-7.

[18] [18] EMOTO S, ISHIGAMI H, YAMASHITA H,et al. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination[J]. Gastric Cancer, 2012, 15(2): 154-161. DOI:10.1007/s10120-011-0091-8.

[19] [19] RANA N A, MAHMOOD A, ROBERT H M,et al. Laboratory evaluation and pathological features of bone marrow metastasis in non-haematological malignancies[J]. J Coll Physicians Surg Pak,2022, 32(10): 1367-1369. DOI:10.29271/jcpsp.2022.10.1367.

[20] [20] WEBB A, SCOTT-MACKIE P, CUNNINGHAM D,et al. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer[J]. Eur J Cancer, 1996, 32A(1): 63-68. DOI:10.1016/0959-8049(95)00504-8.

[21] [21] ASANO Y, YAMAMOTO N, DEMURA S,et al. The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer[J/OL]. Front Oncol, 2022, 12: 871675[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/35433422/. DOI:10.3389/fonc.2022.871675.

[22] [22] WANG K Y, GU Y, LIAO Y H,et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain[J]. J Clin Invest,2020, 130(7): 3603-3620. DOI:10.1172/JCI133334.

[23] [23] JOSEPH G J, JOHNSON D B, JOHNSON R W. Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms[J/OL]. J Bone Oncol, 2023, 43: 100505[2025-03-09]. http://dx.doi.org/10.1016/j.jbo.2023.100505. DOI:10.1016/j.jbo.2023.100505.

[24] [24] ZHU Y J, CHANG X S, ZHOU R,et al. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold”immune characteristics in non-small cell lung cancer[J]. Lung Cancer, 2022, 166: 189-196. DOI:10.1016/j.lungcan.2022.03.006.

[25] [25] REINSTEIN Z Z, PAMARTHY S, SAGAR V,et al. Overcoming immunosuppression in bone metastases[J]. Crit Rev Oncol Hematol,2017, 117: 114-127. DOI:10.1016/j.critrevonc.2017.05.004.

[26] [26] YIN J J, POLLOCK C B, KELLY K. Mechanisms of cancer metastasis to the bone[J]. Cell Res, 2005, 15(1): 57-62. DOI:10.1038/sj.cr.7290266.

[27] [27] ARELLANO D L, JUREZ P, VERDUGO-MEZA A,et al. Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice[J]. J Bone Miner Res, 2022,37(8): 1446-1463. DOI:10.1002/jbmr.4615.

[28] [28] ZENG Y J, JIN R U. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer[J]. Semin Cancer Biol,2022, 86(Pt 3): 566-582. DOI:10.1016/j.semcancer.2021.12.004.

[29] [29] WANI S A, QUDRAT S, ZUBAIR H,et al. Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review[J]. J Oncol Pharm Pract, 2025, 31(1): 119-127. DOI:10.1177/10781552241275943.

[31] [31] YIN S, ZHAI X H, LI Y Y,et al. Bone metastasis mediates poor prognosis in early-onset gastric cancer: insights into immune suppression, coagulopathy, and inflammation[J/OL]. Cancer Med,2025, 14(5): e70737[2025-03-09]. https://pubmed.ncbi.nlm.nih.gov/40040540/. https://pubmed.ncbi.nlm.nih.gov/40040540/. DOI:10.1002/cam4.70737.